Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(13%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_1
1
13%
Ph phase_2
7
88%

Phase Distribution

1

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
7(87.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Active, not recruiting1
Not yet recruiting1
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (12.5%)
Phase 27 (87.5%)

Trials by Status

active_not_recruiting113%
not_yet_recruiting113%
withdrawn113%
unknown113%
completed450%

Recent Activity

1 active trials
Showing 5 of 8
completedphase_2

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

NCT03911557
not_yet_recruitingphase_2

Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment

NCT07168668
active_not_recruitingphase_2

Prostate Cancer Biomarker Enrichment and Treatment Selection

NCT03385655
withdrawnphase_1

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

NCT03802747
completedphase_2

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

NCT02937818
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03911557Phase 2

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Completed
NCT07168668Phase 2

Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment

Not Yet Recruiting
NCT03385655Phase 2

Prostate Cancer Biomarker Enrichment and Treatment Selection

Active Not Recruiting
NCT03802747Phase 1

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Withdrawn
NCT02937818Phase 2

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Completed
NCT04221555Phase 2

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Unknown
NCT03317457Phase 2

Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Completed
NCT03430895Phase 2

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8